uploads///Repatha and Blincyto

Amgen’s Repatha and Blincyto: How They Did in 3Q17

By

Oct. 11 2020, Updated 12:02 p.m. ET

Repatha revenue trends

In 4Q17, Amgen’s (AMGN) Repatha generated revenues of $98 million, which reflected a 69% growth YoY (year-over-year) and a 10% growth quarter-over-quarter. In 4Q17 in the US and international markets, Repatha generated revenues of $70 million and $28 million, respectively.

In fiscal 2017, Repatha reported revenues of $319 million compared to $141 million in 2016. In 2017 in the US and international markets, Repatha generated revenues of $225 million and $94 million, respectively. Higher unit demand primarily pushed growth in 2017.

Article continues below advertisement

Repatha (evolocumab) is used for diminishing the risk of myocardial infarction, stroke, and coronary revascularization in adult individuals with designated cardiovascular disease. In the cardiology market, Repatha competes with Regeneron’s (REGN) and Sanofi’s Praluent. To know more about Repatha, please refer to Repatha Could Significantly Drive Amgen’s Revenue Growth in 2018.

Blincyto revenue trends

In 4Q17, Blincyto generated revenues of $46 million, which is a 59% growth YoY and a 12% decline quarter-over-quarter. In 4Q17 in the US and international markets, Blincyto generated revenues of $29 million and $17 million, respectively.

In fiscal 2017, Blincyto had revenues of $175 million compared to $115 million in 2016, reflecting a 52% growth YoY. In 2017 in the US and international markets, Blincyto had revenues of $114 million and $61 million, respectively.

Higher unit demand and a slight increase in net selling price primarily contributed to revenue growth for Blincyto in 2017.

Blincyto is intended for the treatment of individuals with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (or ALL). In the ALL drugs market, Blincyto competes with Bristol-Myers Squibb’s (BMY) Sprycel and Novartis’s (NVS) Gleevec and Kymriah.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.